Advertisement

Topics

Latest "Standard & Poor’s" News Stories - Page: 4

03:45 EST 20th January 2019 | BioPortfolio

Here are the most relevant search results for "Standard & Poor’s" found in our extensive news archives from over 250 global news sources.

More Information about Standard & Poor’s on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Standard & Poor’s for you to read. Along with our medical data and news we also list Standard & Poor’s Clinical Trials, which are updated daily. BioPortfolio also has a large database of Standard & Poor’s Companies for you to search.

Showing "Standard Poor" News Articles 76–100 of 3,300+

Tuesday 15th January 2019

FDA Additionally Clears RAPID™ Imaging Platform for Use in Selecting Acute Stroke Patients for Clot Removal

Approval Puts RAPID in a Class of Its Own for Diagnosing and Treating Stroke iSchemaView, the worldwide leader in advanced imaging for stroke, today announced that the FDA has cleared the RAPID neuroimaging platform for use in selecting stroke patients who are likely to benefit from endovascular thrombectomy (clot removal). Specifically, this additiona...


Stool Processing Method Might Be Important for Efficacy in Fecal Transplantation Protocols

Odds of short-term remission in ulcerative colitis were higher using anaerobically prepared pooled donor stool versus standard autologous stool.

CAQH Develops the First Provider Data Management Solution for Delegated Groups with Support from Accenture

Cloud-based platform leverages micro-services and a highly flexible database to enable improved user experience Accenture (NYSE:ACN) has helped CAQH, a non-profit healthcare alliance, launch a new technol


Certara Supported 90+ Percent of US FDA Novel New Drug Approvals for Fourth Consecutive Year

FDA’s record-breaking year for approvals affirms high value provided by model-informed drug development Certara®, the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, today reported that more than 90% of novel new drug approvals by the US Food and Drug Administration (FDA) in 2018 ...

Stillwater Ingredients Fuels VYBES, Largest Hemp CBD Beverage by Market Share in the U.S.

Closing Out First Year in Distribution, VYBES Expands to 1,400 stores in 17 states, and More Than 1.1 Million Bottles Produced As it rounds out its first year of sales, VYBES, a line of organic, ready-to-drink beverages, has become the largest Hemp CBD beverage by market share in the U.S. – based on first-year sales, national expansion, distribution ...

European Commission approves Opdivo for advanced renal cell carcinoma

The European Commission has approved Bristol-Myers Squibb's Opdivo in combination with low-dose Yervoy for first-line treatment of patients with intermediate and poor risk advanced renal cell carcinoma (RCC).

Align Clinical CRO Publishes New Operational Data Exchange Standard for Life Sciences Industry Input

Industry group’s first technology standard to make it easier for sponsors and CROs to share information during clinical trials NEW YORK–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/CROs?src=hash” target=”_blank”gt;#CROslt;/agt;–Align Clinical CRO, a life sciences industry standards group that includes eight leading contract research organizatio...

Stem Cell Transplant May Help Some With Aggressive MS

TUESDAY, Jan. 15, 2019 -- A stem cell transplant may help some people with multiple sclerosis (MS) when standard drugs fail, a new clinical trial finds. The study focused on 110 patients with aggressive cases of MS: Their symptoms had flared up at...

Presbia meets audit milestone under revised ISO standard

Ireland-based Presbia has completed its ISO 13485:2016 audit with no major findings, allowing it to proceed with efforts to b -More- 

Cigna Employees Kick Off $25 Million Healthier Kids For Our Future Initiative By Combatting Childhood Hunger Globally

Global health service company Cigna Corporation (NYSE:CI) today kicks off Healthier Kids for Our Future, a $25 million five-year global initiative to improve the health and well-being of children. Cigna's 74,000 global employees will work together to put children on a healthier path, starting with reducing childhood hunger and improving nutrition in local ...

Keytruda cuts risk of death by 31% in esophageal cancer trial

MSD’s Keytruda has cut the risk of death by 31% in patients with esophageal or esophagogastric junction carcinoma or adenocarcinoma who progressed after standard therapy. The results, from the phase 3 KEYNOTE-181 study, pave the way for yet anothe...

Early Extubation to Noninvasive Ventilation Does Not Reduce Time to Liberation From All Mechanical Ventilation

In this multicenter, randomized, open-label trial of patients who failed a spontaneous breathing trial, those who were extubated to noninvasive ventilation did not have a shorter time to liberation from any form of mechanical ventilation compared to those who were randomized to protocolized standard weaning.

Recent Developments in Breast Cancer

(MedPage Today) -- New HER2+ standard, CDK4/6 survival bump, skipping chemotherapy

Constantia Flexibles Introduces Flexible Blister Packaging

Portable packaging provides barrier integrity similar to standard blister solutions

Effect of standard light illumination on electrolyte’s stability of lithium-ion batteries based on ethylene and di-methyl carbonates

Arbor Biosciences and the IWGSC Partner on Wheat Exome

Arbor Biosciences, a worldwide leader in next generation sequencing (NGS) target enrichment and synthetic biology, announces their partnership with the International Wheat Genome Sequencing Consortium (IWGSC), an international organization dedicated to developing a gold-standard reference genome for bread wheat cv. Chinese Spring. This strategic partnership will provide IWGSC members with a standa...

The Importance of System Calibration and Verification for a TOC Instrument

Measuring total oxidizable carbon (TOC) in water has become a standard quality test for many industries...

Monday 14th January 2019

[Comment] New developments on interferon-γ release assays for tuberculosis diagnosis

To diagnose or exclude tuberculosis can be challenging because of the varied clinical signs and the limitations of diagnostic tests. Tuberculosis diagnosis has evolved from autopsies and histology to radiography and microbiological tests, with culture as the ultimate gold standard. Interferon-γ release assays (IGRAs) measure T-cell responses to Mycobacterium tuberculosis-specific antigens. Althou...

Merck’s KEYTRUDA® (pembrolizumab) Reduced Risk of Death by 31 Percent Compared to Chemotherapy in Previously Treated Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Expressed PD-L1 (CPS ≥10)

Results from Phase 3 KEYNOTE-181 Trial to be Presented at 2019 Gastrointestinal Cancers Symposium (ASCO GI) Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of results from KEYNOTE-181, a Phase 3 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the second-line treat...

$BMY EC Approves Opdivo Plus Low-Dose Yervoy for First-Line Treatment of Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma

$BMY EC Approves Opdivo Plus Low-Dose Yervoy for First-Line Treatment of Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma

European Commission Approves Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) for First-Line Treatment of Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma

First I-O/I-O combination regimen to receive European approval for previously untreated patients with advanced renal cell carcinoma Approval based on results from Phase 3 CheckMate -214 trial Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission has approved the combination of Opdivo (nivolumab) 3 mg/kg p...

QIAGEN’s QuantiFERON®-TB Gold Plus Gains Approval in Canada

Fourth generation latent TB blood test provides flexible workflow and novel CD8 technology for a more complete picture of patients' immune response to tuberculosis infection QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the Health Canada regulatory approval of QuantiFERON®-TB Gold Plus (QFT®-Plus) as an in vitro diagnostic t...

NeurologyLive ™ Launches Peer Exchange ‘Chronic Migraine: New Paradigms in Management’

The expert panel focuses on the specific information and educational needs of health care professionalsinvolved in the diagnosis and treatment of chronic migraine NeurologyLive™, a digital and print media enterprise platform dedicated to providing health care professionals treating neurological diseases direct access to expert practice-changin...

Using CRISPR-Cas Screens to Reveal Fitness Genes and to Map Genetic Interactions, New Webinar Hosted by Xtalks

Genomic analyses are yielding a host of new information on the multiple genetic abnormalities associated with specific types of cancer. A comprehensive description of cancer-associated genetic abnormalities can improve our ability to classify tumors into clinically relevant subgroups and sometimes identify drivers. In this webinar, learn how the Moffat lab’s screening workflow helps to discern t...

Immunotherapy/VEGF Inhibitor Combos to Define Frontline Standard in mRCC

Sumanta K. Pal, highlights the different combination regimens that are making headlines in the treatment of patients with metastatic renal cell carcinoma.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks